DEVELOPMENT OF GABAPENTIN-LOADED SOLID LIPID NANOPARTICLE FOR ALLEVIATING SEIZURE ACTIVITY IN PICROTOXIN AND BICUCULLINE-INDUCED RATS
DOI:
https://doi.org/10.22159/ijap.2024v16i6.51157Keywords:
Gabapentin, Box-behnken design, Solid lipid nanoparticle, Glyceryl tripalmitate, Poloxamer-188, In vitro release, In vivo anti-convulsion studyAbstract
Objective: The current research aimed to prepare gabapentin-loaded Solid Lipid Nanoparticles (SLN) for alleviating seizure activity in picrotoxin and bicuculline-induced Wistar rats.
Methods: Gabapentin-loaded SLNs were formulated using a Box-Behnken experimental design with three-level three-factor consisting of 17 experimental runs by micro-emulsification. Three independent parameters were considered in this study, namely sodium glyceryl tripalmitate (A), RPM (B), and Poloxamer-188 (C). Particle size, drug release, and Encapsulation Efficiency (EE) as dependent variables. The formulation was evaluated for drug release, EE, Attenuated Total Reflection (ATR), Differential Scanning Calorimetry (DSC), X-ray diffraction (XRD), surface morphology, particle size, zeta potential, in vivo anti-convulsion study.
Results: The data collected during the experiment includes the measurements of EE (Encapsulation Efficiency), drug release at the 12th h, and particle size. It was reported that formulations containing a high concentration of Glyceryl tripalmitate (50%) had a high Encapsulation Efficiency (EE). The in vitro release results indicate that F17 demonstrated a maximum drug concentration of 99.99% within a 12 h. The optimization process was conducted using mathematical and graphical methods. From ATR spectra, it was found that there are no such major interactions between gabapentin and excipients. A significant endothermal peak was seen in the DSC investigation at 208.81 °C. X-ray diffraction revealed that gabapentin was present in the crystalline form. Drug crystals and SLN were seen to be dispersed and scattered from Scanning Electron Microscope (SEM). The optimized formulation's particle size was found to be 203.4 nm, the Polydispersity Index (PI) of 0.426, and the zeta value of 16.5 mV; indicating stability. Following a lethal and chronic dosage of picrotoxin, the gabapentin-SLN exhibited a higher anticonvulsant efficacy, according to in vivo research on rats (p<0.05).
Conclusion: Compared to the Bicuculline model, the optimized SLN demonstrated superior outcomes regarding seizure initiation in the Picrotoxin-induced convulsion.
Downloads
References
Stafstrom CE, Carmant L. Seizures and epilepsy: an overview for neuroscientists. Cold Spring Harb Perspect Med. 2015;5(6):6:a022426. doi: 10.1101/cshperspect.a022426, PMID 26033084.
Praveen P, Panchaksharimath P, Rohith V. Cardiac autonomic dysfunction in patients with epilepsy. Int J Pharm Pharm Sci. 2023;15(10):13-6. doi: 10.22159/ijpps.2023v15i10.49095.
World Health Organization. Epilepsy. Fact sheet. Available from: https://www.who.int/news-room/fact-sheets/detail/epilepsy [Last accessed on 07 Feb 2024]
Arya RK, Juyal V, Kunwar N. Preparation of carbamazepine chitosan nanoparticles for improving nasal absorption. J Drug Delivery Ther. 2015 May-Jun;5(3):101-8. doi: 10.22270/jddt.v5i3.1090.
Lopalco A, Ali H, Denora N, Rytting E. Oxcarbazepine loaded polymeric nanoparticles: development and permeability studies across in vitro models of the blood-brain barrier and human placental trophoblast. Int J Nanomedicine. 2015 Mar 11;10:1985-96. doi: 10.2147/IJN.S77498, PMID 25792832.
Esfandyari Manesh M, Javanbakht M, Dinarvand R, Atyabi F. Molecularly imprinted nanoparticles prepared by miniemulsion polymerization as selective receptors and new carriers for the sustained release of carbamazepine. J Mater Sci Mater Med. 2012;23(4):963-72. doi: 10.1007/s10856-012-4565-y, PMID 22331374.
Leyva Gomez G, Gonzalez Trujano ME, Lopez Ruiz E, Couraud PO, Wekslerg B, Romero I. Nanoparticle formulation improves the anticonvulsant effect of clonazepam on the pentylenetetrazole induced seizures: behavior and electroencephalogram. J Pharm Sci. 2014;103(8):2509-19. doi: 10.1002/jps.24044, PMID 24916334.
Jain AS, Date AA, Nagarsenker MS. Design characterization and evaluation of anti-epileptic activity of nanoprecipitating preconcentrate of carbamazepine. Drug Deliv Lett. 2013;3(1):61-9. doi: 10.2174/2210304x11303010009.
Ruiz ME, Castro GR. Nanoformulations of antiepileptic drugs: in vitro and in vivo studies. Methods in pharmacology and toxicology antiepileptic drug discovery; 2016. p. 299-326. doi: 10.1007/978-1-4939-6355-3_16.
Sowmya C, Suriya Prakaash KK, Abrar AH. Solid lipid nanoparticles: modern progress in nose-to-brain transduction. Int J App Pharm. 2023 Apr;15(4):20-6. doi: 10.22159/ijap.2023v15i4.47897.
Partridge B, Eardley A, Morales BE, Campelo SN, Lorenzo MF, Mehta JN. Advancements in drug delivery methods for the treatment of brain disease. Front Vet Sci. 2022 Sep;9:1039745. doi: 10.3389/fvets.2022.1039745, PMID 36330152.
Bhargavi C, Raghuveer P. Enhancing nose-to-brain delivery of piribedil: development of a nanosuspension dispersed in nasal in situ gelling system. Int J App Pharm. 2024 May 7;16(3):86-101. doi: 10.22159/ijap.2024v16i3.50242.
Gangurde PK, Kumar L, Kumar L. Lamotrigine lipid nanoparticles for effective treatment of epilepsy: a focus on brain targeting via nasal route. J Pharm Innov. 2019;14(2):91-111. doi: 10.1007/s12247-018-9343-z.
Kumar P, Sharma G, Gupta V, Kaur R, Thakur K, Malik R. Oral delivery of methylthioadenosine to the brain employing solid lipid nanoparticles: pharmacokinetic behavioral and histopathological evidences. AAPS PharmSciTech. 2019;20(2):74. doi: 10.1208/s12249-019-1296-0, PMID 30631981.
Swidan SA, Ghonaim HM, Samy AM, Ghorab MM. Efficacy and in vitro cytotoxicity of nanostructured lipid carriers for paclitaxel delivery. J App Pharm Sci. 2016;6(9):18-26. doi: 10.7324/JAPS.2016.60903.
Kelidari HR, Saeedi M, Akbari J, Morteza Semnani K, Gill P, Valizadeh H. Formulation optimization and in vitro skin penetration of spironolactone loaded solid lipid nanoparticles. Colloids Surf B Biointerfaces. 2015 Apr 1;128:473-9. doi: 10.1016/j.colsurfb.2015.02.046, PMID 25797482.
Ahmed A, Ghourab M, Shedid S, Qushawy M. Optimization of piroxicam niosomes using central composite design. Int J Pharm Pharm Sci. 2013;5(3):229-36.
Qushawy M, Nasr A, Abd Alhaseeb M, Swidan S. Design optimization and characterization of a transfersomal gel using miconazole nitrate for the treatment of candida skin infections. Pharmaceutics. 2018;10(1):26. doi: 10.3390/pharmaceutics10010026, PMID 29473897.
Knezevic NN, Aijaz T, Candido KD, Kovaleva S, Lissounov A, Knezevic I. The effect of once-daily gabapentin extended-release formulation in patients with postamputation pain. Front Pharmacol. 2019 May 15;10:504. doi: 10.3389/fphar.2019.00504, PMID 31156433.
Gad S, Ahmed AM, Ghourab MM, Queshawy MK. Design formulation and evaluation of piroxicam niosomal gel. Int J PharmTech Res. 2014;6(1):185-19.
Neves AR, Queiroz JF, Reis S. Brain targeted delivery of resveratrol using solid lipid nanoparticles functionalized with apolipoprotein E. J Nanobiotechnology. 2016;14:27. doi: 10.1186/s12951-016-0177-x, PMID 27061902.
Eltahawy NA, Ibrahim AK, Radwan MM, Zaitone SA, Gomaa M, ElSohly MA. Mechanism of action of antiepileptic ceramide from red sea soft coral sarcophyton auritum. Bioorg Med Chem Lett. 2015;25(24):5819-24. doi: 10.1016/j.bmcl.2015.08.039, PMID 26577694.
Alhaj MW, Zaitone SA, Moustafa YM. Fluvoxamine alleviates seizure activity and downregulates hippocampal GAP-43 expression in pentylenetetrazole kindled mice: role of 5-HT3 receptors. Behav Pharmacol. 2015;26(4):369-82. doi: 10.1097/FBP.0000000000000127, PMID 25590967.
Abd Elghafour BA, El Sayed NM, Ahmed AA, Zaitone SA, Moustafa YM. Aspirin and (or) omega-3 polyunsaturated fatty acids protect against corticohippocampal neurodegeneration and downregulate lipoxin A4 production and formyl peptide receptor-like 1 expression in pentylenetetrazole kindled rats. Can J Physiol Pharmacol. 2017;95(4):340-8. doi: 10.1139/cjpp-2016-0060, PMID 28060522.
Aldawsari HM, Eid BG, Neamatallah T, Zaitone SA, Badr JM. Anticonvulsant and neuroprotective activities of Phragmanthera austroarabica extract in pentylenetetrazole-kindled mice. Evid Based Complement Alternat Med. 2017;2017:5148219. doi: 10.1155/2017/5148219, PMID 28465705.
Gad ES, Zaitone SA, Moustafa YM. Pioglitazone and exenatide enhance cognition and downregulate hippocampal beta-amyloid oligomer and microglia expression in insulin-resistant rats. Can J Physiol Pharmacol. 2016;94(8):819-28. doi: 10.1139/cjpp-2015-0242, PMID 27389824.
Shahid M, Subhan F, Ahmad N, Ali G, Akbar S, Fawad K. Topical gabapentin gel alleviates allodynia and hyperalgesia in the chronic sciatic nerve constriction injury neuropathic pain model. Eur J Pain. 2017 Apr;21(4):668-80. doi: 10.1002/ejp.971, PMID 27862616.
Joseph E, Reddi S, Rinwa V, Balwani G, Saha R. Design and in vivo evaluation of solid lipid nanoparticulate systems of olanzapine for acute phase schizophrenia treatment: investigations on antipsychotic potential and adverse effects. Eur J Pharm Sci. 2017;104:315-25. doi: 10.1016/j.ejps.2017.03.050, PMID 28408348.
Scioli Montoto S, Sbaraglini ML, Talevi A, Couyoupetrou M, Di Ianni M, Pesce GO. Carbamazepine loaded solid lipid nanoparticles and nanostructured lipid carriers: physicochemical characterization and in vitro/in vivo evaluation. Colloids Surf B Biointerfaces. 2018;167:73-81. doi: 10.1016/j.colsurfb.2018.03.052, PMID 29627680.
Garg A, Bhalala K, Tomar DS, Wahajuddin. In situ single-pass intestinal permeability and pharmacokinetic study of developed lumefantrine loaded solid lipid nanoparticles. Int J Pharm. 2017;516(1-2):120-30. doi: 10.1016/j.ijpharm.2016.10.064, PMID 27989820.
Kendall DA, Fox DA, Enna SJ. Effect of gamma vinyl GABA on bicuculline-induced seizures. Neuropharmacology. 1981;20(4):351-5. doi: 10.1016/0028-3908(81)90008-3, PMID 7290349.
Jahangiri L, Kesmati M, Najafzadeh H. Evaluation of anticonvulsive effect of magnesium oxide nanoparticles in comparison with conventional MgO in diabetic and non-diabetic male mice. Basic Clin Neurosci. 2014;5(2):156-61. PMID 25337374.
Published
How to Cite
Issue
Section
Copyright (c) 2024 POOJA AGARWAL, VASUDHA BAKSHI
This work is licensed under a Creative Commons Attribution 4.0 International License.